Study summary
Semaglutide lowered the risk of kidney failure and death by 24%
24%lower risk of major kidney events
What was tested
Weekly semaglutide 1.0 mg against placebo in people with type 2 diabetes and chronic kidney disease.
What they found
- Major kidney events (kidney failure, large drop in kidney function, or death) were 24% less likely.
- Cardiovascular deaths were also lower.
What it means
Added GLP-1 drugs to SGLT2 inhibitors and finerenone as kidney-protecting treatments in diabetes.
Last reviewed 2026-11-16 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.